PTP-1B Inhibitor (AstraZeneca/Pfizer)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NamePTP-1B Inhibitor (AstraZeneca/Pfizer)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein-tyrosine phosphatase 1B inhibitors
TargetsProtein-tyrosine phosphatase 1B
Therapy Area/IndicationsObesityDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer IncAstrazeneca Plc
Active IndicationsN/A
Inactive IndicationsObesityDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A